"Approved Clinician" or "Section 12(2)" courses are not delivered at the Trust, but staff may have received this training elsewhere (including Maudsley Learning).
SLaM's E&D team update staff profiles on LEAP with the date of AC/s12 expiry, and this status exempts those staff from mandatory MCA and DoLS.
As of January 2025, the Trust's Revalidation Project Officer (Andy Lumsden) is notifying SLaM's E&D team of any AC/s12 status changes, and we will update LEAP accordingly.
If for any reason, LEAP has not been updated with your AC/s12 status, you may still send us the approval panel letter as evidence.
Exemption from MCA & DoLS training
These "Approved Clinician" trainings cover the same ground, but at a higher level, as MCA (Mental Capacity Act) and DoLS (Denial of Liberty Safeguards) trainings.
So naturallly you do not need to attend those trainings, which would otherwise be mandatory, for the period of your Approved Clinician training validity. As stated above, you simply need to send evidence of this to the Training department.
For "Approved Clinician", "Section 12(2)" & "CAMHS Section 12" versions, this exemption from MCA & DoLS training applies.
Guidance for Training team (E&D admins) on updating profiles for "Approved Clinician" / MCA & DoLS exemption
Notification by the Trust's Revalidation Project Officer (Andy Lumsden) (to LEAP inbox) is enough. No further evidence needed.
"Edit profile" for that user, and specifically set the date-flags, as here:

You do not need to make changes to audiences on LEAP. Setting the date-flags as described here, will remove these staff from the MCA / DoLS audiences until the expiry date of their Approved Clinician training. The audiences will in turn update these users' MAST profile.
You should ideally set both dates - but it is the second one which feeds into audience rules.
"Approved Clinician" and "Section 12(2)" are normally renewed every 5 years, so you would normally set the exemption for 5 years, as in screenshot above (or as per the expiry date on the evidence sent to us).
Comments
0 comments
Article is closed for comments.